Methylene tetrahydrofolate reductase gene polymorphisms and their association with methotrexate toxicity: A meta-analysis

Pharmacogenetics and Genomics

Volumn 22, Issue 2, 2012, Pages 117-133

  Spyridopoulou, Kalliopi P ^a   Dimou, Niki L ^b   Hamodrakas, Stavros J ^a   Bagos, Pantelis G ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF CENTRAL GREECE   (Greece)

Author keywords

gene polymorphisms; meta analysis; methotrexate toxicity; methylene tetrahydrofolate reductase

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLIC ACID; FOLINIC ACID; METHOTREXATE;

ALLELE; BLOOD TOXICITY; BONE DISEASE; CELL TRANSPLANTATION; DISEASE ASSOCIATION; GASTROINTESTINAL INFECTION; GASTROINTESTINAL TOXICITY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LOW DRUG DOSE; LUNG TOXICITY; MEDLINE; META ANALYSIS; METASTASIS; MUCOSA INFLAMMATION; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; THROMBOSIS; TOXIC HEPATITIS; VITAMIN SUPPLEMENTATION;

EID: 84855927189     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32834ded2a     Document Type: Review

References (90)

1. Kremer JM. Methotrexate and emerging therapies. Clin Exp Rheumatol 1999; 17:S43-S46. (Pubitemid 29503356)
2. Kremer JM. Methotrexate and emerging therapies. Rheum Dis Clin North Am 1998; 24:651-658. (Pubitemid 28416815)
3. Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am 1997; 23:739-755. (Pubitemid 27490240)
4. Cronstein BN. Molecular therapeutics. Methotrexate and its mechanism of action, Arthritis Rheum 1996; 39:1951-1960.
5. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002; 4:266-273. (Pubitemid 34716307)
6. Baggott JE, Vaughn WH, Hudson BB. Inhibition of 5-aminoimidazole-4- carboxamide ribotide transformylase, adenosine deaminase and 50-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J 1986; 236:193-200. (Pubitemid 16095531)
7. Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum 2004; 50:1370-1382. (Pubitemid 38608058)
8. Neves C, Jorge R, Barcelos A. The network of methotrexate toxicity. Acta Reumatol Port 2009; 34:11-34.
9. Braun J, Rau R. An update on methotrexate. Curr Opin Rheumatol 2009; 21:216-223.
10. Rozen R. Molecular genetics of methylenetetrahydrofolate reductase deficiency. J Inherit Metab Dis 1996; 19:589-594. (Pubitemid 26315907)
11. Goyette P, Sumner JS, Milos R, Duncan AM, Rosenblatt DS, Matthews RG, et al. Human methylenetetrahydrofolate reductase: isolation of cDNA mapping and mutation identification. Nat Genet 1994; 7:551. (Pubitemid 24308346)
12. Van der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998; 62:1044-1051. (Pubitemid 28199004)
13. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64:169-172. (Pubitemid 28453294)
14. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10:111-113.
15. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283:2008-2012. (Pubitemid 30214957)
16. Pan Z, Trikalinos TA, Kavvoura FK, Lau J, Ioannidis JP. Local literature bias in genetic epidemiology: an empirical evaluation of the chinese literature. PLoS Med 2005; 2:e334.
17. Conn VS, Valentine JC, Cooper HM, Rantz MJ. Grey literature in metaanalyses. Nurs Res 2003; 52:256-261.
18. Bagos PG. A unification of multivariate methods for meta-analysis of genetic association studies. Stat Appl Genet Mol Biol 2008; 7:Article 31.
19. Bagos PG, Nikolopoulos GK. A method for meta-analysis of case-control genetic association studies using logistic regression. Stat Appl Genet Mol Biol 2007; 6:Article 17.
20. Petiti DB. Meta-analysis decision analysis and cost-effectiveness analysis. Oxford: Oxford University Press; 1994.
21. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-560. (Pubitemid 37088507)
22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188. (Pubitemid 17189972)
23. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50:1088-1101.
24. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-634. (Pubitemid 27387172)
25. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 1999; 18:2693-2708. (Pubitemid 29481404)
26. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992; 327:248-254.
27. Lau J, Schmid CH, Chalmers TC. Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. J Clin Epidemiol 1995; 48: 45-57, discussion 59-60.
28. Ioannidis JP, Trikalinos TA. Early extreme contradictory estimates may appear in published research: the Proteus phenomenon in molecular genetics research and randomized trials. J Clin Epidemiol 2005; 58:543-549. (Pubitemid 40692719)
29. Bagos PG, Nikolopoulos GK. Generalized least squares for assessing trends in cumulative meta-analysis with applications in genetic epidemiology. J Clin Epidemiol 2009 (In press).
30. Van Ede AE, Laan RF, Blom HJ, Huizinga TW, Haagsma CJ, Giesendorf BA, et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 2001; 44:2525-2530. (Pubitemid 33049330)
31. Bohanec Grabar P, Logar D, Lestan B, Dolzan V. Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. Eur J Clin Pharmacol 2008; 64:1057-1068.
32. Aggarwal P, Naik S, Mishra KP, Aggarwal A, Misra R. Correlation between methotrexate efficacy and toxicity with C677T polymorphism of the methylenetetrahydrofolate gene in rheumatoid arthritis patients on folate supplementation. Indian J Med Res 2006; 124:521-526. (Pubitemid 46157711)
33. Zeng QY, Wang YK, Xiao ZY, Chen SB. Pharmacogenetic study of 5,10-methylenetetrahydrofolate reductase C677T and thymidylate synthase 3R/2R gene polymorphisms and methotrexate-related toxicity in Chinese Han patients with inflammatory arthritis. Ann Rheum Dis 2008; 67:1193-1194.
34. Urano W, Taniguchi A, Yamanaka H, Tanaka E, Nakajima H, Matsuda Y, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002; 12:183-190. (Pubitemid 34596782)
35. Taniguchi A, Urano W, Tanaka E, Furihata S, Kamitsuji S, Inoue E, et al. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice. Pharmacogenet Genomics 2007; 17:383-390. (Pubitemid 46763383)
36. Krull KR, Brouwers P, Jain N, Zhang L, Bomgaars L, Dreyer Z, et al. Folate pathway genetic polymorphisms are related to attention disorders in childhood leukemia survivors. J Pediatr 2008; 152:101-105. (Pubitemid 350265921)
37. Schmeling H, Biber D, Heins S, Horneff G. Influence of methylenetetrahydrofolate reductase polymorphisms on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis. J Rheumatol 2005; 32:1832-1836. (Pubitemid 41324827)
38. Bernbeck B, Mauz-Korholz C, Zotz RB, Gobel U. Methylenetetrahydrofolate reductase gene polymorphism and glucocorticoid intake in children with ALL and aseptic osteonecrosis. Klin Padiatr 2003; 215:327-331. (Pubitemid 38064631)
39. Azarpira N, Ramzi M, Aghdaie MH, Daraie M, Geramizadeh B. Methylenetetrahydrofolate reductase C677T genotypes and clinical outcome following hematopoietic cell transplant. Exp Clin Transplant 2007; 5:693-697. (Pubitemid 351146928)
40. Sugimoto K, Murata M, Onizuka M, Inamoto Y, Terakura S, Kuwatsuka Y, et al. Decreased risk of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with the 5,10-methylenetetrahydrofolate reductase 677TT genotype. Int J Hematol 2008; 87:451-458.
41. Imanishi H, Okamura N, Yagi M, Noro Y, Moriya Y, Nakamura T, et al. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet 2007; 52:166-171. (Pubitemid 46188292)
42. Campalani E, Arenas M, Marinaki AM, Lewis CM, Barker JN, Smith CH. Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J Invest Dermatol 2007; 127:1860-1867. (Pubitemid 47075365)
43. Ghodke Y, Chopra A, Joshi K, Patwardhan B. Are thymidylate synthase and methylene tetrahydrofolate reductase genes linked with methotrexate response (efficacy, toxicity) in Indian (Asian) rheumatoid arthritis patients? Clin Rheumatol 2008; 27:787-789.
44. Chiusolo P, Reddiconto G, Farina G, Mannocci A, Fiorini A, Palladino M, et al. MTHFR polymorphisms' influence on outcome and toxicity in acute lymphoblastic leukemia patients. Leuk Res 2007; 31:1669-1674. (Pubitemid 350051399)
45. Pihusch M, Lohse P, Reitberger J, Hiller E, Andreesen R, Kolb HJ, et al. Impact of thrombophilic gene mutations and graft-versus-host disease on thromboembolic complications after allogeneic hematopoietic stem-cell transplantation. Transplantation 2004; 78:911-918. (Pubitemid 39298537)
46. Seidemann K, Book M, Zimmermann M, Meyer U,Welte K, Stanulla M, et al. MTHFR 677 (C->T) polymorphism is not relevant for prognosis or therapyassociated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95. Ann Hematol 2006; 85:291-300. (Pubitemid 43732651)
47. Toffoli G, Russo A, Innocenti F, Corona G, Tumolo S, Sartor F, et al. Effect of methylenetetrahydrofolate reductase 677C-> T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer 2003; 103:294-299. (Pubitemid 36076421)
48. Kalayoglu-Besisik S, Caliskan Y, Sargin D, Gurses N, Ozbek U. Methylenetetrahydrofolate reductase C677T polymorphism and toxicity in allogeneic hematopoietic cell transplantation. Transplantation 2003; 76:1775-1777. (Pubitemid 38032434)
49. Kim SK, Jun JB, El-Sohemy A, Bae SC. Cost-effectiveness analysis of MTHFR polymorphism screening by polymerase chain reaction in Korean patients with rheumatoid arthritis receiving methotrexate. J Rheumatol 2006; 33:1266-1274. (Pubitemid 44025139)
50. Fijnheer R, Roest M, Haas FJ, De Groot PG, Homocysteine Derksen RH. methylenetetrahydrofolate reductase polymorphism, antiphospholipid antibodies, and thromboembolic events in systemic lupus erythematosus: a retrospective cohort study. J Rheumatol 1998; 25:1737-1742. (Pubitemid 28439267)
51. Shimasaki N, Mori T, Torii C, Sato R, Shimada H, Tanigawara Y, et al. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 2008; 30:347-352. (Pubitemid 351643456)
52. Kim I, Lee KH, Kim JH, Ra EK, Yoon SS, Hong YC, et al. Polymorphisms of the methylenetetrahydrofolate reductase gene and clinical outcomes in HLA-matched sibling allogeneic hematopoietic stem cell transplantation. Ann Hematol 2007; 86:41-48. (Pubitemid 46138317)
53. Ranganathan P, Culverhouse R, Marsh S, Mody A, Scott-Horton TJ, Brasington R, et al. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 2008; 35:572-579. (Pubitemid 351500051)
54. Kishi S, Griener J, Cheng C, Das S, Cook EH, Pei D, et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 2003; 21:3084-3091. (Pubitemid 46606289)
55. Jazbec J, Kitanovski L, Aplenc R, Debeljak M, Dolzan V. No evidence of association of methylenetetrahydrofolate reductase polymorphism with occurrence of second neoplasms after treatment of childhood leukemia. Leuk Lymphoma 2005; 46:893-897. (Pubitemid 40959678)
56. Chiusolo P, Reddiconto G, Casorelli I, Laurenti L, Sora F, Mele L, et al. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol 2002; 13:1915-1918. (Pubitemid 36040780)
57. Berkun Y, Levartovsky D, Rubinow A, Orbach H, Aamar S, Grenader T, et al. Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann Rheum Dis 2004; 63:1227-1231. (Pubitemid 39273498)
58. Gemmati D, Ongaro A, Tognazzo S, Catozzi L, Federici F, Mauro E, et al. Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival. Haematologica 2007; 92:478-485. (Pubitemid 350144293)
59. Ruiz-Arguelles GJ, Coconi-Linares LN, Garces-Eisele J, Reyes-Nunez V. Methotrexate-induced mucositis in acute leukemia patients is not associated with the MTHFR 677T allele in Mexico. Hematology 2007; 12:387-391. (Pubitemid 47487846)
60. Warren RB, Smith RL, Campalani E, Eyre S, Smith CH, Barker JN, et al. Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. Br J Dermatol 2009; 160:438-441.
61. Kumagai K, Hiyama K, Oyama T, Maeda H, Kohno N. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med 2003; 11:593-600.
62. Wessels JA, De Vries-Bouwstra JK, Heijmans BT, Slagboom PE, Goekoop-Ruiterman YP, Allaart CF, et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with singlenucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 2006; 54:1087-1095. (Pubitemid 43672921)
63. Murphy N, Diviney M, Szer J, Bardy P, Grigg A, Hoyt R, et al. Donor methylenetetrahydrofolate reductase genotype is associated with graft-versus-host disease in hematopoietic stem cell transplant patients treated with methotrexate. Bone Marrow Transplant 2006; 37:773-779.
64. Shimasaki N, Mori T, Samejima H, Sato R, Shimada H, Yahagi N, et al. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 2006; 28:64-68.
65. Aplenc R, Thompson J, Han P, La M, Zhao H, Lange B, et al. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res 2005; 65:2482-2487. (Pubitemid 40490161)
66. Tsuchiya N, Inoue T, Narita S, Kumazawa T, Saito M, Obara T, et al. Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol 2008; 180:2389-2395.
67. Van Kooten Niekerk PB, Schmiegelow K, Schroeder H. Influence of methylene tetrahydrofolate reductase polymorphisms and coadministration of antimetabolites on toxicity after high dose methotrexate. Eur J Haematol 2008; 81:391-398.
68. Hughes LB, Beasley TM, Patel H, Tiwari HK, Morgan SL, Baggott JE, et al. Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann Rheum Dis 2006; 65:1213-1218. (Pubitemid 44277399)
69. Weisman MH, Furst DE, Park GS, Kremer JM, Smith KM,Wallace DJ, et al. Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum 2006; 54:607-612. (Pubitemid 43228638)
70. Robien K, Bigler J, Yasui Y, Potter JD, Martin P, Storb R, et al. Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute graft-versus-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia. Biol Blood Marrow Transplant 2006; 12:973-980.
71. Herrlinger KR, Cummings JR, Barnardo MC, Schwab M, Ahmad T, Jewell DP. The pharmacogenetics of methotrexate in inflammatory bowel disease. Pharmacogenet Genomics 2005; 15:705-711. (Pubitemid 41345322)
72. Fisher MC, Cronstein BN. Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J Rheumatol 2009; 36:539-545.
73. Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol 2009; 146:489-503.
74. Gervasini G. Polymorphisms in methotrexate pathways: what is clinically relevant, what is not, and what is promising. Curr Drug Metab 2009; 10:547-566.
75. Van Ede AE, Laan RF, Blom HJ, De Abreu RA, Van de Putte LB. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 1998; 27:277-292. (Pubitemid 28176234)
76. Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007; 65:168-173. (Pubitemid 351412127)
77. Merrill JT, Shen C, Schreibman D, Coffey D, Zakharenko O, Fisher R, et al. Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: a mechanism for methotrexateinduced nodulosis in rheumatoid arthritis. Arthritis Rheum 1997; 40:1308-1315. (Pubitemid 27430143)
78. Kooloos WM, Wessels JA, Van der Straaten T, Allaart CF, Huizinga TW, Guchelaar HJ. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. Pharmacogenomics 2010; 11:163-175.
79. Trevino LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D, et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 2009; 27:5972-5978.
80. Hider SL, Thomson W, Mack LF, Armstrong DJ, Shadforth M, Bruce IN. Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX. Rheumatology (Oxford) 2008; 47:1156-1159. (Pubitemid 352038219)
81. Pierik M, Rutgeerts P, Vlietinck R, Vermeire S. Pharmacogenetics in inflammatory bowel disease. World J Gastroenterol 2006; 12:3657-3667. (Pubitemid 43950942)
82. Herrlinger KR, Jewell DP. Review article: interactions between genotype and response to therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2006; 24:1403-1412. (Pubitemid 44657116)
83. Vucic N, Frleta M, Petrovic D, Ostojic V. Thrombophilia, preeclampsia and other pregnancy complications. Acta Med Croatica 2009; 63:297-305.
84. Kurzawinska G, Seremak-Mrozikiewicz A, Drews K, Barlik M, Mrozikiewicz PM. Genetic conditioned changes in activity of 5,10-methylenetetrahydrofolate reductase (MTHFR) and recurrent miscarriages. Ginekol Pol 2009; 80:762-767.
85. Greene ND, Stanier P, Copp AJ. Genetics of human neural tube defects. Hum Mol Genet 2009; 18:R113-R129.
86. Frankenburg FR. The role of one-carbon metabolism in schizophrenia and depression. Harv Rev Psychiatry 2007; 15:146-160. (Pubitemid 47237771)
87. Taioli E, Garza MA, Ahn YO, Bishop DT, Bost J, Budai B, et al. Meta-and pooled analyses of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and colorectal cancer: a HuGE-GSEC review. Am J Epidemiol 2009; 170:1207-1221.
88. Trabetti E. Homocysteine, MTHFR gene polymorphisms, and cardiocerebrovascular risk. J Appl Genet 2008; 49:267-282.
89. Salas M, Hofman A, Stricker BH. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol 1999; 149:981-983. (Pubitemid 29246861)
90. Harten P. Reducing toxicity of methotrexate with folic acid. Z Rheumatol 2005; 64:353-358.